Axon's EBITDA Growth Obscures Deepening Margin Risks as Cost Pressures Mount

What happened

Axon Enterprise recently reported 36% EBITDA growth with margin expansion, according to a Zacks article questioning sustainability amid rising costs. However, the DeepValue master report reveals that while Axon boasts strong demand indicators like 125% net revenue retention and $14.4 billion in future contracted bookings, it faces significant financial headwinds, including tariff-driven gross margin compression and stock-based compensation expenses. In FY2025, adjusted gross margin declined to 62.6% from 63.2%, primarily due to global tariffs, and the company swung to a GAAP operating loss of -$62.1 million despite 33.5% revenue growth. Management targets steady margins in 2026, but guidance assumes a 15% global tariff rate and $590-$620 million in SBC, highlighting persistent cost challenges that could undermine profitability. Critical analysis suggests the market's focus on top-line growth overlooks the lack of operating leverage and margin volatility, raising doubts about the stock's premium valuation.

Implication

The combination of strong EBITDA growth with underlying margin weakness signals that Axon's profitability is not yet resilient, risking multiple compression if costs escalate further. High valuations, such as a P/E of 319x, price in sustained improvement, but any slippage in net revenue retention below 115% or continued tariff impacts could trigger sharp downside. Investors must closely monitor quarterly reports for evidence of margin stabilization and consistent backlog conversion, as these are critical to validating the growth narrative. The DeepValue report's 'WAIT' rating is reinforced, emphasizing that entry points should be delayed until clearer signs of cost control and operating leverage emerge. Ultimately, while growth metrics are impressive, the investment case remains asymmetric with more downside risk until financial discipline is demonstrated.

Thesis delta

The new article does not alter the core investment thesis but underscores existing concerns about margin sustainability amid cost pressures. No shift is warranted; the thesis remains that Axon offers high growth with elevated risks, and investors should wait for confirmation of margin resilience before committing capital. This reinforces the cautious approach, as the spotlight on costs validates the need for patience in monitoring key indicators like NRR and gross margins.